Table 1.
Patient- and eye-specific characteristics at the time of the first subtenon triamcinolone acetate injection
| Characteristics | N (%) |
|---|---|
| Unilateral uveitis | 12 (40%) |
| Male patients | 15 (50%) |
| Diagnosis | |
| Pars planitis | 19 (63%) |
| Chronic anterior uveitis | 4 (13%) |
| Panuveitis | 3 (10%) |
| HLA-B27 associated recurrent uveitis | 3 (10%) |
| Vogt-Koyanagi-Harada | 1 (3%) |
| Presence of ME | 18/48 eyes (37.5%) |
| Presence of ONE | 9/48 eyes (18.8%) |
| Presence of cataracts | 9/48 eyes (18.8%) |
| Medications prior to STA | |
| Topical corticosteroids | 28 (93.3%) |
| Oral corticosteroids | 10 (33.3%) |
| Systemic immunosuppressants | 7 (23.3%) |
| IOP-lowering medication | 2 (6.7%) |
| Mean age at first STA injection | 13.1 years (range 7–18) |
| Patients that received ≥ 1 STA injections | 15 (50%) |
ME Macular edema, ONE optic nerve edema, IOP intraocular pressure, STA subtenon triamcinolone acetonide